#294 Real World Evidence for COVID-19 Vaccines
CLINICAL QUESTION
What is the real-world effectiveness for currently available COVID-19 vaccines?
BOTTOM LINE
Similar to clinical trials, real world cohort and case-control studies find COVID-19 infections are reduced by >90% with two doses of mRNA vaccines. Single doses of either mRNA or AstraZeneca vaccine decreases infections by ~60% and hospitalizations by 70-80%. Vaccine effectiveness appears similar for variants of concern and are safe for pregnant women.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- From relatively short cohort/case-control studies or registries. Fully vaccinated defined as 7- or 14-days post-second dose.
- Israel national vaccination (Pfizer) program of 6.5 million adults ≥16 years old.1 New COVID-19 cases in the program’s initial 10 weeks was compared to vaccine status. Full vaccination decreased risk of:
- All COVID-19 infections: By 97%.
- Hospitalizations and deaths: By 98% and 99% respectively.
- Limitations: The same individuals contributed time to unvaccinated, partially vaccinated and fully vaccinated calculations.
- United Kingdom case-control study, persons ≥70 years with COVID-19 (n=44,590) linked to vaccine status.2 Single dose of either Pfizer or AstraZeneca reduced:
- Symptomatic infections: ~60% (~1 month after either vaccine).
- Hospitalizations: 80% (either vaccine).
- Death: ~85% [Pfizer (AstraZeneca death rates not reported)].
- Ontario four-month case-control study, adults ≥16 years:3
- Single-dose (Pfizer or Moderna) reduced:
- Symptomatic infection: 60%.
- Hospitalization or death: 70%.
- Two-doses reduced:
- Symptomatic infection: 91%.
- Hospitalization or death: 98%.
- Single-dose (Pfizer or Moderna) reduced:
- Findings similar to clinical trials.4
- Variants of Concern (VOC):
- Two doses of Pfizer or AstraZeneca reduces symptomatic delta variant infections or hospitalizations similar to non-VOC infections.5
- Pfizer or Moderna vaccination reduces symptomatic infection or hospitalizations in four current VOC (alpha, beta/gamma, delta) similar to non-VOC.6
- Two doses are better than one.6
- Safety in Pregnancy:
- 35,691 pregnant women received Pfizer or Moderna vaccine (29% 1st trimester, 43% second trimester, 26% third trimester):7
- Adverse pregnancy outcomes with vaccine same as baseline risk.7
- Babies born to pregnant women with COVID-19 are twice as likely to develop severe perinatal morbidity and mortality.8
- Pregnant women with COVID-19 have 50% greater risk of maternal morbidity or mortality.8
- 35,691 pregnant women received Pfizer or Moderna vaccine (29% 1st trimester, 43% second trimester, 26% third trimester):7
- Pregnant women should be offered COVID-19 vaccine.9
- Recommendations for vaccinated individuals available: Canada or United States.10,11
Latest Tools for Practice
#379 Bumpin’ Up the Protection? RSV Vaccine in Pregnancy
How effective and safe is the respiratory syncytial virus (RSV) vaccine (AbrysvoTM) when given during pregnancy?
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
Good info
Good
Good review
confirms knowledge